Eyal Gabbai

Director at NurExone Biologic

Capital raised by NurExone Biologic

$2.2M+$442K latest round

3 Form D filings · first filed Apr 2025

CURRENT ROLE: Director
SECTOR: Biotech
COMPANY FILINGS: 3
TEAM ON FILE: 3
FOUNDED: —
30D INTEREST: —

Career

1 company on file

NurExone BiologicBiotechsince Apr 2025

Director

Listed on NurExone Biologic's Form D filings

Company filings

via EDGAR · Form D for NurExone Biologic3

DateCompanyFormAmountRole on filing

Jun 30, 2026NurExone BiologicForm D+$442K—

Form DJun 30, 2026 · NurExone Biologic+$442Knot a signer

Aug 20, 2025NurExone BiologicForm D+$148K—

Form DAug 20, 2025 · NurExone Biologic+$148Knot a signer

Apr 9, 2025NurExone BiologicForm D+$1.6M—

Form DApr 9, 2025 · NurExone Biologic+$1.6Mnot a signer

Overview

Last filing Jun 30, 2026

Eyal Gabbai is on file as Director at NurExone Biologic. NurExone Biologic has 3 Form D filings on record, $2.2M raised in total.

Teammates

NurExone Biologic · 2

Eran OvadyaChief Financial OfficerSigner Gadi RiesenfeldDirector

Products

NurExone Biologic · 1

ExoPTENRegenerative Medicine

ExoPTEN is an exosome-loaded nanodrug designed to facilitate neuron regeneration and restore motor, sensory, and functional abilities in patients who have recently experienced acute spinal cord injuries.